AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

AFT Pharmaceuticals Limited

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Samih Darwazah

Hikma Pharmaceuticals PLC

Novaliq is a biopharmaceutical company focusing on the development and commercialization of ocular therapeutics based on EyeSol®, a water-free ophthalmic technology. The company is involved in R&D programs for various ophthalmic diseases.

Novaliq

AFT Pharmaceuticals develops, licenses and sells a wide range of pharmaceuticals to help improve health and wellbeing, self-described.

Metric
Company Name	AFT Pharmaceuticals Limited	Hikma Pharmaceuticals PLC	Novaliq
Symbol	AFT	HIK
MSH ID	COM:AFTPHARM	COM:HIKMA	COM:NOVALIQ
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - Specialty & Generic	Biotechnology
Country	NZ	GB	DE
Stage
Employee Count	110	9.10K
Website	aftpharm.com	hikma.com	novaliq.com
LinkedIn		hikma-pharmaceuticals
Founders

Metric
Market Cap	180.44M	51.46M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	113.99M	2.88B
Revenue (LTM)
Revenue (NTM)
Gross Profit	51.49M	1.39B
EBITDA	15.00M	871M
Operating Income	13.83M	367M
Net Income	9.11M	190M
EPS	0.09	0.86
Diluted EPS	0.09	0.85
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.46	0.50
Operating Profit Margin	0.12	0.24
EBITDA Margin	0.13	0.30
Net Profit Margin	0.08	0.09
Return on Equity	0.30	0.13
Return on Assets	0.14	0.06
Return on Capital Employed	0.30	0.21

COM:AFTPHARM

AFT Pharmaceuticals

Last Close

2.71

25/11 04:00

Market Cap

309.35M

Beta: -

Volume Today

40.14K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	36.81	57.06
P/B Ratio	5.35	2.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.46	2.00
EV Multiple	11.51	6.03

Metric
Days Sales Outstanding	92.80	287.13
Days Payables Outstanding	96.79	288.23
Days Inventory Outstanding	141.07	236.69
Operating Cycle	204.75	354.84
Cash Conversion Cycle	109.61	205.25
Asset Turnover	1.77	0.62

Metric
Operating Cash Flow	14.90M	608M
Free Cash Flow	9.35M	404M
Cash Flow to Debt	1.38	0.51
Operating Cash Flow/Sales	0.14	0.21
Free Cash Flow Yield	-0.02	0.03

Metric
Cash & Equivalents	7.02M	205M
Accounts Receivable	1.46M
Inventory	28.62M	891M
Goodwill		388M
Debt to Capitalization	0.34	0.36
Debt to Assets	0.26	0.28
Current Ratio	2.38	1.79
Quick Ratio	1.23	0.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue	0.04	0.06
SG&A to Revenue	0.07	0.20